HeyJaredPharmaceutical Positioning
Pharmaceutical Positioning - developing Version 2 of the book in real time
- Indexed issues, last 90 days
- 6
- Latest publication
- Sep 13, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 16, 2026
Latest issues
An idea is a seeing (and most “ideas” in pharma are not) (opens the original)
Read excerpt
(Etymology again - I hope that’s OK… Maybe some genealogy too…)We talk about ideas as if they were inventions (or, the start of an invention). Something you have. Something you generate in a workshop and leave at the end of a deck under “strategic options.”The word is older and more awkward than that.Greek idéa is the look of a thing: its appearance, its kind, the pattern by which you recognise it. It comes from ideîn, to see. The same root gives eîdos - visible form - and oîda, “I know,” which
The Benefit of the Doubt (opens the original)
Read excerpt
Every early asset is being given the benefit of the doubt already. The only question is who is directing it.That phrase belongs to the law, not pharma. But the underlying problem is the same. When the evidence is incomplete, you still have to decide what to do with the gap. You can leave it unattended. You can fill it with analogy. You can fill it with wishful thinking. Or you can organise it.Thanks for reading Pharmaceutical Positioning! Subscribe for free to receive new posts and support my
Polate: The Missing Verb in Pharmaceutical Positioning (opens the original)
Read excerpt
I’ve played enough with etymology in the blog - I hope I’m allowed some neology…Ries and Trout told us positioning is not what you do to a product - it’s what you do to the mind of the prospect. I’ve spent enough of this newsletter arguing the opposite: for pharma, positioning is absolutely what you do to a product, because the molecule itself is still being decided long after the “mind of the prospect” framing assumes it’s finished. Polation is where that argument gets its mechanism.<div class=
Just-So Positioning (opens the original)
Read excerpt
In the High and Far-Off Times, O Best Beloved, before the molecule had a name or a Phase III readout, there lived a curious little compound that sat in a vial and wondered what it might become.The other compounds said, “Wait for the numbers. The numbers will tell you who you are.”But this compound was impatient. It went walking early and met the Big Idea.The Big Idea stretched it, shaped it, chose its endpoints and its language, prepared the soil around it, and whispered: “You will become the du
The new/ better book (opens the original)
Read excerpt
My new book is done. I’ve aimed to make it more ‘practical’ than the first, so there are rules, processes and methodologies. It’s with a couple of reviewers who I trust deeply, so it might expand from its 100 or so pages, but it should be with you soon (I’ll be honest - it could be shorter, if they say that I’ve overdone some things…). A couple of questions where I’d welcome your feedback, if you don’t mind…I don’t need it to make money. I’m enjoying doing positioning again, where I’m allowed to
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.